Uncategorized

Protocol design optimization and timely engagement of regulators are the crux of optimized, patient-centric clinical trials.

SK bioscience announced that H.E Dr. Jean Kaseya, Director General of Africa CDC visited SK bioscience headquarters on November 3 to discuss collaboration with the Partnerships for African Vaccine Manufacturing.

KangaBio announced that the U.S. FDA has granted official approval for their independent R&D clinical trial application for KGX101.

MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, announced positive top-line results from its global Phase 2 ARGO trial evaluating the efficacy and safety of the Nanobody® sonelokimab in patients with active psoriatic arthritis.

Tokyo, Japan and Cambridge, UK,06 November 2023 – Sosei Group Corporation has been notified by Pfizer that it has entered a new oral small molecule GLP-1 receptor agonist into a Phase 1 clinical trial.

Ambry Genetics, a prominent leader in clinical genomic testing and a subsidiary of REALM IDx, Inc., unveiled at the American Society of Human Genetics annual meeting results of a study published in JAMA Oncology that assessed the cumulative impact of paired DNA and RNA testing on detecting disease-causing germline genetic variants and resolution of variants

A recent report by Tufts Medical Center reveals impressive approval rates for durable cell and gene therapies, but experts urge caution over persistent safety and accessibility concerns.

Olink Holding AB announced that Novogene Asia Pacific Middle East and Africa has adopted the Olink Explore HT platform to deliver advanced next-generation proteomics technology to the scientific community in the region.

Elpiscience Biopharmaceuticals, Inc. presented studies for its innovative immunotherapeutic molecules at the SITC 2023 Annual Meeting, including KG2A/NKG2C dual-targeting antibody ES015-2, a high affinity LILRB1 specific blocking antibody ES008-a, and the first-in-class anti-CD39/TGF-βRII bifunctional fusion protein ES014.

GC Biopharma announced 1 Nov. 2023 that it has applied for the marketing approval of “GC1109”, an anthrax vaccine jointly developed by GC Biopharma and the Korea Disease Control and Prevention Agency, to the Korean Ministry of Food and Drug Safety.